Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
J Pediatr Hematol Oncol
; 39(4): e183-e186, 2017 05.
Article
em En
| MEDLINE
| ID: mdl-28338569
ABSTRACT
Ewing sarcoma is a highly resistant disease with a <10% chance of survival at 5 years after failure of frontline chemotherapy. This is a case report of an Ewing sarcoma patient with metastatic disease recurrence <2 years after standard chemotherapy/radiation who achieved a durable and sustained complete response after 2 series of treatments with Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy) serially manufactured from first and second recurrences with ELISPOT assay correlation. Results support justification of further testing of Vigil with ELISPOT assay as a biomarker to assess level of immune response and correlation with disease control.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Sarcoma de Ewing
/
Compostos Benzidrílicos
/
Vacinas Anticâncer
/
Imunoterapia
Tipo de estudo:
Diagnostic_studies
Limite:
Adolescent
/
Female
/
Humans
Idioma:
En
Revista:
J Pediatr Hematol Oncol
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Marrocos